Literature DB >> 29296025

Genome-wide common and rare variant analysis provides novel insights into clozapine-associated neutropenia.

S E Legge, M L Hamshere, S Ripke, A F Pardinas, J I Goldstein, E Rees, A L Richards, G Leonenko, L F Jorskog, K D Chambert, D A Collier, G Genovese, I Giegling, P Holmans, A Jonasdottir, G Kirov, S A McCarroll, J H MacCabe, K Mantripragada, J L Moran, B M Neale, H Stefansson, D Rujescu, M J Daly, P F Sullivan, M J Owen, M C O'Donovan, J T R Walters.   

Abstract

This corrects the article DOI: 10.1038/mp.2016.97.

Entities:  

Year:  2017        PMID： 29296025      PMCID： PMC5754465          DOI： 10.1038/mp.2017.214

Source DB:  PubMed          Journal:  Mol Psychiatry        ISSN： 1359-4184            Impact factor:   15.992


Correction to: Molecular Psychiatry (2017) 22: 1502-1508; advance online publication, 12 July 2017; doi: 10.1038/mp.2016.97 In the first paragraph of the Results section and Figure 1, the authors incorrectly referred to the finding of SNP rs77897117. The correct SNP is rs77897177.
Figure 1

PowerPoint slide

PowerPoint slide The corrected figure appears in previous page.
  8 in total

1.  Genome-wide association analyses of symptom severity among clozapine-treated patients with schizophrenia spectrum disorders.

Authors:  C Okhuijsen-Pfeifer; M Z van der Horst; C A Bousman; B Lin; K R van Eijk; S Ripke; Y Ayhan; M O Babaoglu; M Bak; W Alink; H van Beek; E Beld; A Bouhuis; M Edlinger; I M Erdogan; A Ertuğrul; G Yoca; I P Everall; T Görlitz; K P Grootens; S Gutwinski; T Hallikainen; E Jeger-Land; M de Koning; M Lähteenvuo; S E Legge; S Leucht; C Morgenroth; A Müderrisoğlu; A Narang; C Pantelis; A F Pardiñas; T Oviedo-Salcedo; J Schneider-Thoma; S Schreiter; E Repo-Tiihonen; H Tuppurainen; M Veereschild; S Veerman; M de Vos; E Wagner; D Cohen; J P A M Bogers; J T R Walters; A E Anil Yağcıoğlu; J Tiihonen; A Hasan; J J Luykx
Journal:  Transl Psychiatry       Date:  2022-04-07       Impact factor: 7.989

2.  A multimodal study of a first episode psychosis cohort: potential markers of antipsychotic treatment resistance.

Authors:  Kun Yang; Luisa Longo; Zui Narita; Nicola Cascella; Frederick C Nucifora; Jennifer M Coughlin; Gerald Nestadt; Thomas W Sedlak; Marina Mihaljevic; Min Wang; Anshel Kenkare; Anisha Nagpal; Mehk Sethi; Alexandra Kelly; Pasquale Di Carlo; Vidyulata Kamath; Andreia Faria; Peter Barker; Akira Sawa
Journal:  Mol Psychiatry       Date:  2021-10-12       Impact factor: 13.437

3.  Adverse drug reactions triggered by the common HLA-B*57:01 variant: a molecular docking study.

Authors:  George Van Den Driessche; Denis Fourches
Journal:  J Cheminform       Date:  2017-03-04       Impact factor: 5.514

Review 4.  The many roads to psychosis: recent advances in understanding risk and mechanisms.

Authors:  Carrie E Bearden; Jennifer K Forsyth
Journal:  F1000Res       Date:  2018-12-03

5.  Genetics of clozapine-associated neutropenia: recent advances, challenges and future perspective.

Authors:  Sophie E Legge; James Tr Walters
Journal:  Pharmacogenomics       Date:  2019-02-15       Impact factor: 2.533

Review 6.  Clozapine rechallenge and initiation despite neutropenia- a practical, step-by-step guide.

Authors:  Edward Silva; Melanie Higgins; Barbara Hammer; Paul Stephenson
Journal:  BMC Psychiatry       Date:  2020-06-05       Impact factor: 3.630

7.  Clozapine re-challenge and initiation following neutropenia: a review and case series of 14 patients in a high-secure forensic hospital.

Authors:  Edward Silva; Melanie Higgins; Barbara Hammer; Paul Stephenson
Journal:  Ther Adv Psychopharmacol       Date:  2021-06-21

8.  Clozapine rechallenge following neutropenia using granulocyte colony-stimulating factor: A Quebec case series.

Authors:  Laurent Béchard; Olivier Corbeil; Maude Plante; Marc-André Thivierge; Charles-Émile Lafrenière; Marc-André Roy; Marie-France Demers
Journal:  J Psychopharmacol       Date:  2021-07-06       Impact factor: 4.153
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.